RxDoctor Payments DataLook up a doctor →

David Bonney, DO

Dermatology · West Orange, NJNPI 1548476385

Payments from drug & device makers

$32,422in general payments, 2019–2025

Across 1,724 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$5K
  • AbbVie$4K
  • Medimetriks Pharmaceuticals, Inc.$3K
  • Johnson & Johnson$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • plus $16K from 38 others

What the payments were for

  • Consulting fees$5,47517%
  • Travel & lodging$330%
  • Food & beverage$26,35381%
  • Education$5612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,422 in reported general payments places this provider in the 85th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$396,199
Medicare patients
740
Services billed
5,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa16$334,181
TremfyaGuselkumab11$152,712
Dupixent PenDupilumab33$120,406
Taltz AutoinjectorIxekizumab12$81,378
Dupixent SyringeDupilumab13$51,424
OpzeluraRuxolitinib Phosphate19$37,491
JubliaEfinaconazole13$20,094
Tacrolimus107$14,428
Calcipotriene40$7,898
Betamethasone Dipropionate144$6,393
Ketoconazole346$5,983
Ciclopirox121$4,368
Clobetasol Propionate73$2,352
Mupirocin284$2,233
Tretinoin44$1,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,085$152,71211 claims
Incyte CorporationOpzelura$1,100$37,49119 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$841$20,09413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 394 dermatology providers in New Jersey.

Other dermatology in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →